Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. (DYN) had an officer, Doug Kerr, file a Rule 144 notice covering a planned sale of 5,000 shares of common stock through broker Stifel Nicolaus & Company. The filing also lists prior sales of Dyne common stock by Kerr over the preceding three months.
Dyne Therapeutics director Jason P. Rhodes reported indirect sales of 2,586,928 shares of Common Stock of DYN on August 13–14, 2026. The shares were sold primarily by Atlas Venture-affiliated funds at weighted average prices around $25–$26.20 per share, pursuant to a Rule 10b5-1 trading plan adopted on July 13, 2026. The footnotes state that the shares are held by various Atlas Venture funds and partnerships, and Rhodes disclaims Section 16 beneficial ownership except to the extent of his pecuniary interest.
Dyne Therapeutics, Inc. officer Johanna Friedl-Naderer, Chief Commercial Officer, reported an automatic sale of 226 shares of common stock on 2026-08-13 at a weighted average price of $26.28 per share. The shares were sold to satisfy tax withholding obligations arising from vesting of restricted stock units under a Rule 10b5-1 binding contract, and not as a discretionary trade. Following this transaction, she directly holds 153,982 shares, which include 119,928 unvested RSUs.
Dyne Therapeutics, Inc. reported that Chief Medical Officer Douglas Kerr sold 1,556 shares of common stock on August 13, 2026 at a weighted average price of $26.28 per share. The shares were automatically sold to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units under a pre-arranged agreement treated as a Rule 10b5-1 "binding contract", so the transaction did not represent a discretionary trade. Following this sale, Kerr directly held 167,599 shares of common stock, including 140,001 unvested RSUs.
Dyne Therapeutics, Inc. CEO & President John Cox reported a sale of 4,986 shares of Common Stock on August 13, 2026 at a weighted average price of $26.28 per share. The shares were automatically sold to satisfy tax withholding obligations arising from vesting of restricted stock units granted on February 12, 2026 under a restricted stock unit agreement that constitutes a “binding contract” consistent with the affirmative defense under Rule 10b5‑1, so the transaction is not a discretionary trade. Following this sale, Cox directly holds 363,165 shares, including 248,314 unvested RSUs, and indirectly holds 18,000 shares in each of four trusts for the benefit of a child of the reporting person.
Dyne Therapeutics, Inc. officer Erick Lucera (Chief Financial Officer) reported selling 1,797 shares of common stock on August 13, 2026 at a weighted average price of $26.28 per share. The sale was an automatic disposition to satisfy tax withholding obligations upon vesting of restricted stock units under a pre-existing agreement treated as a Rule 10b5-1 binding contract, and is described as not a discretionary trade. Following this transaction, Lucera directly holds 119,766 shares, including 106,451 unvested RSUs.